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Abstract 
Gene therapy or cell transplantation therapy has made great progress in recent years. We 
overview mediatophore as a potential medical usage for gene and transplantation 
therapies in the nervous system. The 16-kDa proteolipid mediatophore was shown to 
mediate the secretion of acetylcholine in a Ca2+-dependent manner. Mediatophore is 
known to be identical to the transmembrane c-subunit of the V0 sector of the vacuolar 
proton ATPase (ATP6V0C).  Recent development of structural understandings reveals 
that ATP6V0C is not a simple pore-forming stalk enable to permeate transmitters. 
Therefore, it is time to review this topic revisited from the recent knowledge on ATPase.  
Acetylcholine, serotonin, and dopamine (DA) are released from cell soma and/or 
dendrites if ATP6V0C is expressed in cultured cells. Adeno-associated viral 
vector-mediated gene transfer of rat ATP6V0C into the mouse caudate putamen 
enhanced the depolarization-induced overflow of endogenous DA in the 
6-hydroxydopamine-lesioned substantia nigra. Motor impairment was ameliorated more 
efficiently in hemiparkinsonian model mice when ATP6V0C was expressed with DA 
synthesizing enzymes in comparison to the gene delivery of three DA synthesizing 
enzymes without ATP6V0C. These results suggest that ATP6V0C mediates 
neurotransmitter release from the cell soma and/or dendrites in the brain in an autocrine 
or paracrine fashion and may thus apply as a useful tool for gene therapy, cell 
transplantation therapy and inducible pluripotent stem cell therapy for Parkinson’s 
disease, Alzheimer’s disease and psychiatric disorders in the future. 
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Introduction 
Secretion is one of major topics in the physiological science field [1-6]. Most cells are 
naturally equipped with the vesicular-soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (v-SNARE) that ensures the vesicular traffic and 
endo-exocytosis as well as neurotransmitter release [7,8]. However, another attractive 
secretion mechanism has been known since 1966 [9]. In the electric eels, acetylcholine 
(ACh) is released in a paracrine fashion from the soma of electric organ cells and acts 
on nicotinic ACh receptors in adjacent cells to accumulate a voltage of up to 1,000 V 
[10-12]. Mediatophore, a 15-kDa proteolipid, has been originally found in the 
presynaptic membrane of the Torpedo electric organ. French physiologists characterized  
this protein from the electric organ synaptosome and showed its remarkable ACh 
translocation properties (see review [13-16]).  
 
Acetylcholine release by mediatophore 
The much clear answer for the role of mediatophore in ACh release was rendered by 
projects in which reconstruction of mediatophore in a variety of cells that had no release 
machinery for ACh [13]. Israel, Dunat and their colleagues found that many cells were 
unable to release ACh in response to a calcium influx: this was the case for splenic cells, 
hepatocytes, erythrocytes, myeloma cells and several neuroblastoma cells [13-15]. In 
Marshall Nirenberg’s laboratory at the National Institutes of Health, USA from 
1965-1975, cholinergic neuroblastoma or neuroblastoma-derived hybrid culture cell 
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lines were cloned [17-20]. Neuroblastoma clones that are inactive with respect to 
neurotransmitter synthesis were also isolated. N18TG-2 neuroblastoma cells were 
typical such cell type. Contrarily, other culture cells were very competent for ACh 
release provided they were loaded with the transmitter: the C6BU-1 glioma cell line 
followed by the fibroblastic L cell line, PC12, Neuro 2A and NG108-15 cells 
[13-15,21-25]. Interestingly, the ACh release mechanism that is expressed by the latter 
cells was calcium dependent, when release was elicited by an influx of calcium with the 
calcium ionophore A23187 [11,13,16]. Fisher et al. [13] noticed that fibroblasts 
genetically modified to express choline acetyltransferase (ChAT) became able to release 
the transmitter by A23187 [26,27]. Some of other cell lines such as NG108-15 cells 
expressed voltage-dependent calcium channels that can be activated after depolarization 
[24,25], so that Ca2+ dependent ACh release was elicited by electrical stimulation [26]. 
Of particular interest is the series of work of Higashida and his colleagues who studied 
in co-culture with myocytes and neuroblastoma (Neuro 2A) or hybrid cell lines 
(NG108-15, N18TG-2 x C6Bu-1; NBr-10A, N18TG-2 x BRL-30E liver) [19-23], in 
which the detected release was measured as endplate potential of the ACh receptor 
origin [24]. The N18TG2 cells that were transfected with ChAT was insufficient to 
induce transmission at the synapse in co-cultures, and were unable to elicit miniature 
endplate potentials, as similarly as those experiments after loading them with ACh using 
the chemiluminescent ACh detection [16,21,22,27]. In Table 1 opposite cell lines are 
listed: One has a very efficient ACh release mechanism (the C6BU-1 glioma cells); 
another has no capability (the N18TG-2 neuroblastoma cells). The ACh release capacity 
 5 
of NG108-15 or NBt-10A hybrid cells cells seems to be derived from C6Bu-1 glioma or 
Buffalo rat liver BRL-30E cells which equipped with mediatophore, rather than 
N18-TG-2 cells [19,20,23]. 
 
Mediatophore, as an ortholog of ATPase 
Mediatophore was later shown to be an ortholog of the mammalian C subunit of the V0 
transmembrane sector of the vacuolar proton ATPase (ATP6V0C) [10,11,13-15,28,29; 
Figure 1]. ATP6V0C plays a central role in H+ transport as one part of the multi-subunit 
complex of ATPase [30-44]. Israel and his group initially proposed that medatophore 
forms a proteinaceous pore by the six transmemebrane c subunits of ATPase [10,11]. 
However, Israel’s hypothesis about ATP6V0C in neurotransmitter release must be 
delineate by considering that V-ATPase is widely expressed in most types of cells and 
that, if ATP6V0C is indeed non-selectively permeable to cationic neurotransmitters 
[37,42-44]]. It is highly likely that ATP6V0C is also permeable to much smaller ions, 
like Na+ and K+ [44] Thus ionic currents through ATP6V0C might be recordable using 
an electrophysiological technique, when ATP6V0C is overexpressed in the plasma 
membrane. Of course such reports are not available, because nobody has been tested 
along such idea [44]. If ATP6V0C is not permeable to small ions and/or the currents 
through ATP6V0C are not clearly recorded, ATP6V0C might be classified as a 
transporter or an enzyme, and ATP6V0C is unlikely to be permeable to so diverse types 
of neurotransmitter. The amino acid sequence and recently reported structures of the c 
ring of the V0 domain [44] suggest very high hydrophobicity of the inner part of the 
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ring, which seems unsuitable for an ion channel pore. In addition, a direct interaction 
between ATP6V0C and the vesicular SNARE synaptobrevin and associated modulatory 
effects on ACh release have been reported [13,35,36]. Therefore, now it is time to 
carefully re-consider the role of mediatophore/ATP6V0C and thus, revisited it from the 
recent advances in knowledges of vacuolar ATPase. 
 
Serotonin release from NG108-15 cells 
The possibility to increase efflux other transmitters is of particularly interest. NG108-15 
neuroblastoma x glioma hybrid cells or NBr-10A neuroblastoma x Buffalo rat liver cell 
hybrid cells release ACh upon high K+ depolarizing stimulation and evoke endplate 
potentials in muscle cells via electrical stimulation of differentiated NG108-15 or 
NBr10-A cells due to ACh release [20,22-24; Table 1].  
 Falk-Vairant et al. demonstrated the presence of endogenous ATP6V0C in 
NG108-15 cells via western blotting and concluded that the capacity of NG10-15 cells 
to release ACh from the cell soma and/or dendrites is due to ATP6V0C [13-15]. Then, 
we examined whether NG108-15 cells can release serotonin, which is another 
neurotransmitter. First, NG108-15 cells were soaked with [3H]serotonin, and the cells 
were filled with [3H]serotonin by uptake from the extracellular medium. After intensive 
washing, the cells were stimulated with a depolarizing high potassium medium. 
[3H]Serotonin was released in the presence of extracellular Ca2+ but not in the absence 
of Ca2+, showing that this behavior is Ca2+-dependent [45,46]. NG108-15 cells are 
known to have both small clear vesicles and large dense core vesicles. Indeed, Furuya et 
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al. (1985) [45] clearly demonstrated them and suggested serotonin in dense core 
vesicles. Thus the evidence for serotonin in the dense core release through ATP6V0C is 
very weak; instead, it is likely that ATP6V0C just facilitate the exocytosis of 
serotonin-containing vesicles or the release of free serotonine in the cytoplasm 
(cytosolic serotonin). 
 
 
Dopamine release from N18 cells expressing ATP6V0C or NG108-15 cells  
Next, we examined the possibility of DA release in N18 cells transfected with vectors 
containing  (5’ to 3’) forward form of ATP6V0C or the reverse-form of ATP6V0C that 
is newly produced in the expression vector with 3’- to 5’ sequence of ATP6V0C [47]. 
After transfection, the transfected cells were preloaded for 1 h with 1 µM [3H]DA in the 
presence of pargyline, a monoamine oxydase inhibitor that would have been added for 
preventing degradation of [3H]DA [45]. Stimulation with 80 mM K+ in the perfusion 
medium resulted in a detectable increase in [3H]DA release in a Ca2+-dependent fashion 
[45]. However, when identical experiments were performed in N18 cells transfected 
with reverse ATP6V0C, [3H]DA was not released after high-potassium depolarizing 
stimulation. It is worth mentioning that ACh, serotonin and DA share an 
ATP6V0C-dependent mechanism for DA release from the cell soma or dendrites of 
ATP6V0C-expressing neuroblastoma cells or NG108-15 cells with endogenous 
ATP6V0C (Table 1).   
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Effects of ATP6V0C overexpression on dopamine release in the intact mouse brain 
The functional roles of ATP6V0C were elucidated in vivo. Although ATP6V0C is 
expressed in different brain regions (data not shown), ATP6V0C was over-expressed in 
the mouse brain using adeno-associated virus (AAV) vectors individually harboring 
cDNAs of rat ATP6V0C [38],  reverse form ATP6V0C, and ATP6V0C-GFP [47] 
Infection with these viruses in the substantia nigra of the intact mouse brain using the 
microinjection technique [47] revealed ATP6V0C-GFP expression in both tyrosine 
hydroxylase (TH)-positive neurons and TH-negative cells, which were other 
non-neuronal cells, probably astrocytes (see Figure. 1 of ref. 47). 
Armed with this information, DA overflow from the synaptic cleft in the 
mouse striatum after treatment with AAV vectors [47] in the substantia nigra was 
measured using the in vivo microdialysis method [48]. DA release was significantly 
higher in the mice infected with AAV-ATP6V0C under both resting (5 mM extracellular 
potassium concentration) and depolarizing (50 mM) conditions (see Figure 2 of ref. 47). 
In contrast, viral infection with the reverse direction of ATP6V0C had no or little effect 
on DA release, with levels comparable to the control (sham-operated with PBS 
injection) mice.  
 
Behavior in hemiparkinsonian mice with or without ATP6V0C 
First, we generated hemiparkinsonian mice. A 2-μL aliquot of 6-hydroxydopamine 
(6-OHDA) dissolved in 0.02% ascorbic acid in saline was injected into the substantia 
nigra over a period of 2 min at a speed of 1 μL/min (total injected amount: 28 μg of 
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6-OHDA) [47]. The needle was left in place for an additional 3 min and then withdrawn 
slowly. The control animals received PBS in the substantia nigra according to the same 
procedure.  
The motor performance of 6-OHDA-lesioned mice in the unilateral substantia 
nigra was examined based on the latency to fall from the accelerated rotating rod. If the 
fall latency increased, we judged the changed as an effect of recovery from motor 
impairment. Four AAV vectors individually containing three DA synthetic enzymes 
(tyrosine hydroxylase (TH) or aromatic L-amino-acid decarboxylase (AADC) or GTP 
cyclohydrolase I (GCH)) and either one of forward and reverse forms of ATP6V0C were 
infected stereotaxically into the lesion side of the caudoputamen. 6-OHDA-lesioned 
mice treated with three DA-synthesizing enzymes and ATP6V0C displayed significantly 
improved performance on the rotarod (134.2 ± 14.6 s) in comparison to mice treated 
with three DA-related genes plus reverse ATP6V0C (78.1 ± 17.0 s, P < 0.01, n = 5, 
ANOVA; see Figure 2 of ref. 47). Recovery was much greater in these mice than in 
mice treated with these three enzymes alone (75.6 ± 17.2 s) or PBS-treated control mice 
(24.4 ± 12.2 s) (P < 0.01 and 0.001, respectively, in comparison to the value obtained 
for mice treated with all three enzymes plus ATP6V0C). The observed recovery of mice 
with the three enzymes plus ATP6V0C or its reverse form was approximately 73% or 
36% of that observed in the wild-type mice (174.5 ± 12.4 s), respectively [47]. 
 
Amphetamine-induced rotations in hemiparkinsonian mice with or without 
overexpressing ATP6V0C 
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d-Amphetamine-induced rotation is a strong predictor of nigral TH cell loss [49,50]. 
Three weeks after lesion generation, the mice exhibited ipsilateral turning induced by 
the intraperitoneal injection of 3 µg/kg of d-amphetamine [47]. The number of rotations 
was significantly decreased in mice transfected with the three enzymes, the three 
enzymes plus reverse ATP6V0C, and the three enzymes plus ATP6V0C in comparison to 
control mice injected with PBS (Table 2). In contrast, in sham-operated mice, no 
rotation was induced by amphetamine [47].  
 
Overview of gene or cell transplantation therapy for neurodegenerative diseases 
In both rodent and non-human primate models of Parkinson’s disease (PD), viral 
vector-mediated gene delivery of one enzyme (AADC) or three DA-synthesizing 
enzymes (TH, AADC, and GCH) into the striatum has been shown to ameliorate motor 
symptoms, with efficient signal transduction of putaminal neurons [47,51-64]. Many 
clinical trials (phase-one and phase-two) of gene therapy for PD were performed using 
AAV vectors [56]. In these protocols, gene transfer of AADC into the human putamen is 
usually combined with oral administration of the precursor 
L-3,4-dihydroxyphenylalanine (L-dopa) [53,54].  Most of the transduced cells are 
medium spiny neurons (MSNs), the principal projection neurons that account for 
90–95% of all neurons in the striatum. After gene transfer, the MSNs synthesize DA in 
addition to their inherent inhibitory neurotransmitter, γ-aminobutyric acid (GABA). 
Gene delivery of DA-synthesizing enzymes would be a useful way to supply DA 
continuously in the putamen (Figure 2).  
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 The nerve terminals of dopaminergic neurons of the substantia nigra (SN) are 
selectively degraded and mostly lost in the putamen of the motor phase of chronic PD 
patients [63]. This observation suggests that even DA synthesized by extrinsic enzymes 
in the putamen could not be released from the nerve endings of dopaminergic neurons. 
Rather, cell-somatal release is likely in transduced neurons (Figure 2), in which the 
fusion of exocytotic vesicles and the vesicular secretory apparatus is not identical to that 
observed in the intact nigral nerve terminals [63,64].  
 Alternatively, if the neurons do not possess the vesicular monoamine 
transporter, DA would not be incorporated into vesicles and not released through 
vesicular exocytosis. On the other hand, the vesicle fusion and its apparatus must be 
more or less similar among different types of neurons [63-67]. In any case, however, the 
evidence for somatic or dendritic release of DA through ATP6V0C in 
non-dopaminergic neurons or glia is likely to be very weak at this moment. For example, 
Jin et al. [47] did not explicitly indicate how many dopaminergic neurons were actually 
destroyed by their unilateral 6-OHDA injection procedure, though functionally 
dopaminergic responses were substantially destroyed. Thus it is still possible that 
injection of the genes of ATP6V0C and DA-synthesizing enzymes into the striatum 
would have just augmented the exocytotic DA release from the remaining dopaminergic 
nerve terminals. Indeed, it has been shown in many studies, including Jin et al. [47], that 
the enzyme introduction alone, i.e. even without ATP6V0C, may significantly improve 
the symptom. 
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It is possible to postulate another mechanism whereby a complex of 
proteolipid channels involved in SNARE fusion may effectively secrete DA from 
DA-accumulating cells in the striatum, as described in yeast and Drosophila [7,65,66]. 
ATP6V0C binds to syntaxin in SNARE complexes [67] or interacts directly with the 
v-SNARE synaptobrevin [35,36], and ATP6V0C may cooperate with SNARE proteins 
and vesicles for release during the late stage of fusion []. DA release through proteolipid 
fusion pores suggests that the vesicles may be recycled without undergoing full fusion 
with the plasma membrane (i.e., the “kiss-and-run” process) [51-54]. 
 
ATP6V0C as a useful gene in the future 
PD is a common neurodegenerative disorder in the elderly [62]. The characteristic 
motor symptoms, which include resting tremor, muscular rigidity, and bradykinesia, are 
caused by a severe decrease in the DA content of the striatum secondary to progressive 
loss of nigrostriatal DA neurons [68]. The refilling of DA in the striatum using extrinsic 
methods is important for functional restoration, regardless of the damage sustained by 
the nigrostriatal DA pathway. With recombinant AAV vectors, gene therapy is becoming 
a feasible therapeutic option for PD. 
Baseline striatal dopaminergic neurotransmission in the normal striatum is 
maintained by tonic synaptic and non-synaptic DA release, which is largely independent 
of changes in neuronal impulse flow in the nigrostriatal pathway. As shown in previous 
studies [51,52,58], neurons and other types of cells were transfected with AAV, although 
the majority of transfected cells were neurons.  
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 We previously detected efficient baseline and L-dopa-induced DA release in 
the AAV-TH/-AADC/-GCH-injected putamen via microdialysis in primates [52], 
indicating that the DA synthesized by these extrinsic enzymes was released. This 
observation suggests that DA is released from the cell soma of the transfected cells via a 
non-synaptic mechanism or from non-neuronal elements, such as astro- or micro-glial 
cells. DA released from nearby cells binds to the DA receptors on GABAergic neurons 
and functions in paracrine or autocrine mode, respectively (Figure 2). Can cytoplasmic 
DA bind to the receptors, even when the DA-binding sites of the receptors are never 
exposed to the cytoplasm once they have been internalized? The papers [56, 57] just 
indicated down- or up-regulation of DA receptors in the presence or absence of 
preceding DA receptor activation, respectively. 
Of course, we pay less consideration to the binding of internalized DA 
receptors in response to alterations in dopaminergic tone [56,57]. 
 
Conclusion 
The mediatophore is of course not sufficient to explain all the release 
properties of a natural synapse [16]. It can only give an partial explanation for the efflux 
of cytosolic and/or vesicular ACh, and probably for the most elementary events related 
to sub-quanta, as mentioned by Israel et al. [11,28]. They tried to analyze what would be 
the effect of transfecting them with a plasmid encoding for ChAT, and then for vesicular 
ACh transporter (VAChT) that allows them to store the transmitter in vesicles [13]. 
Several groups have found that ChAT and VAChT genes are adjacent and co-regulated 
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forming a cholinergic genomic locus (see for example [37]). Though we do not now that 
N18TG-2 cells equip with the VAChT and synaptic vesicles, we cannot exclude the 
possibility that the transfection with ATP6V0C may induce vesicle formation and 
transporter expression. In such case, it is possible that cytosolic as well as vesicular 
ACh is released [69]. 
We described a stronger improvement in movement impairment in mice 
expressing four proteins (TH, AADC, GCH, and ATP6V0C) than in mice expressing 
three proteins (TH, AADC, and GCH), largely due to the facilitated release of DA. We 
discussed these results not from an old view of the pore formed by ATP6V0C, but from 
the current view with various possible mechanisms for transmitter release mainly based 
on the recent structural understandings [44]. Such concept suggests that ATP6V0C may 
be useful in future gene or cell transplantation therapy [70,71]. As ACh and serotonin 
can be released in the same fashion, gene and cell therapies for other diseases related to 
ACh and serotonin, such as Alzheimer’s disease, depression, schizophrenia, and 
syndromic autism, may utilize ATP6V0C in the future. This approach is applicable for 
iPSC therapy for similar categories of diseases [72-74] because better recovery would 
be expected if iPSC contains transmitter synthesizing genes and ATP6V0C, because 
most of iPS cells drived from the skin fibroblasts are likely silent [27]. 
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Table 1. 
Capacity for acetylcholine release and synapse formation with muscle cells in 
neuroblastoma tumor cells with or without ATP6V0C expression. 
 
Cell line  ACh  ACh    Synapse ATP6V0C  
synthesis secretion  formation   expression 
 
NG108-15 ++ ++   ++  ++ 
NBr10A  +++ +++   +++  +++ 
N18  0 0   0  0 
N18+ACh* ++ 0   0  0 
N18+ACh*+V0C  ++ ++   +  ++ 
 
ACh*,   Cells were soaked in solution containing ACh (Ref). The same results was 
obtained by choline acetyltransferase transfection.
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Table 2.  
The number of rotations was significantly decreased in mice. 
 
Mice transfected with  Rotations/3 min (% Recovery) 
3 enzymes    14.9 ± 1.2**  (53) 
3 enzymes + reverse ATP6V0C  13.9 ± 4.3*  (56)  
3 enzymes plus ATP6V0C    4.0 ± 1.0*** (87) 
PBS     31.7 ± 2.0 (0) 
N = 4, one-way ANOVA followed by Bonferroni’s post-hoc test, F3,12 = 55.44, P < 
0.001. *P < 0.01, **P < 0.002, and ***P < 0.001 in comparison to PBS.  
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Figure legends 
Figure 1. Schema of molecular components of V-ATPase. (A) A cartoon of whole 
v-ATPase. ATP hydrolysis is shown at the peripheral V1 domain composed of A, B, C, 
and other components. The downhill movement of protons is shown in the V0 sector (α, 
c, d and other components.) (B) c subunits in the V0 transmembrane sector of the 
vacuolar proton ATPase. Six c subunits form the stalk or pore. Redrawn from Nishi and 
Forgac (62).  
                                                                                                                                                                                                                                                                                         
Figure 2. Scheme showing autocrine or paracrine secretion of dopamine from cells 
expressing dopamine-synthetic enzyme and ATPVC6. Dopamine (DA) is synthetized 
by AAV-TH/-AADC/-GCH in astrocytes, neurons, and iPSC (yellow) or glutamatergic 
neurons (brown). DA release from the cell soma through the stalk or pore of ATPV0C6. 
DA released from adjacent cells (paracrine) or glutamatergic neurons (autocrine) binds 
to DA receptors at the synaptic or non-synaptic domains on glutamatergic neurons. 
Glutamatergic neurons relay signals via DA receptors activated by DA from 
dopaminergic neurons in the substantia nigra in intact tissue. In the PD brain, DA 
released in an autocrine or paracrine fashion activates DA receptors.  
 
 


